CTIS2024-512639-58-00招募中1 期
First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors - BNT142-01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- BioNTech SE
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For both parts: Histological or cytological documentation of a solid tumor that is metastatic or unrespectable provided as a pathology report., CLDN6-positive tumor sample as assessed by central laboratory testing using a Validated immunohistochemistry (IHC) assay (CLAUDENTIFY®6 IHC-Assay) in formalin-fixed paraffin-embedded (FFPE) neoplastic tissues or alternatively from fresh tissue if archival tissue is unavailable, Measurable disease per RECIST 1.1 (measurable per RECIST 1.1 or evaluable per GCIG criteria for ovarian tumors)., For Part 1 (Dose escalation): Patients with advanced/metastatic ovarian cancer (including fallopian tube and peritoneal), non-squamous non-small cell lung cancer (NSCLC), endometrial, or testicular cancer, for whom there is no available standard therapy likely to confer clinical benefit, or the patient is not a candidate for such available therapy, or patients with not otherwise specified (NOS) tumors, rare tumors and cancer of unknown primary (CUP), not included in the predefined eligible tumor types. Patients must have received all available standard therapies, including targeted therapies based on mutation status, and failed at least first line standard of care (SOC) therapy prior to enrollment
排除标准
- •Prior and concomitant therapy: Chemotherapy, or molecularly-targeted agents within 3 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment., Radiotherapy in the last 6 weeks prior to the first dose of BNT142 (excluding brain radiotherapy for which 3 weeks prior to the first dose of BNT142 is allowed)., Concurrent systemic (oral or intravenous [IV]) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition apart from physiologic corticosteroid replacement therapy., Major surgery within 4 weeks before the first dose of BNT142, Ongoing or active infection requiring intravenous (IV) treatment with anti-infective therapy that has been administered less than 2 weeks prior to the first dose of BNT142., Prior treatment with a CLDN6 targeting therapy., Side effects of any prior therapy or procedures for any medical condition not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v.5) Grade =1, except for anorexia, fatigue, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to Grade =2. Alopecia of any grade is allowed., Medical conditions Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain metastases may be ligible if they: i. Had radiotherapy, surgery or stereotactic surgery for the brain metastases; ii. Have no neurological symptoms (excluding Grade =2 neuropathy); iii. Have stable brain metastasis on the Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) scan within 4 weeks before signing the Informed Consent Form (ICF) iv. Are not undergoing acute corticosteroid therapy or steroid taper., Pregnant or breastfeeding or planning to get pregnant within 6 months of the last dose of BNT142.
研究者
相似试验
进行中（未招募）
1 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6 positive solid tumorsClaudin 6 (CLDN6)-positive advanced solid tumorsMedDRA version: 21.0Level: LLTClassification code 10043302Term: Testicular cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10007460Term: Carcinoma of unknown primarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005481-18-ESBioNTech SE216
尚未招募
2 期
First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumorstumors10027655cancerNL-OMON53910BioNTech SE14
招募中
不适用
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
已完成
不适用
A phase 1, first-in-human, multicenter, open-label, dose-escalation study to characterize the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumorsNL-OMON51895Molecular Partners AG30
尚未招募
1 期
A Safety and Tolerability Study Evaluating CTX320 in Subjects With Elevated Lipoprotein(a) and a History of Atherosclerotic Cardiovascular Disease or Calcific Aortic Valve Stenosis.Cardiovascular - Other cardiovascular diseasesElevated Lipoprotein(a)Calcific Aortic Valve StenosisAtherosclerotic Cardiovascular DiseaseMetabolic and Endocrine - Other metabolic disordersACTRN12623001095651CRISPR Therapeutics AG24